Requirement for diverse, low-abundance peptides in positive selection of T cells

Science

Volumn 283, Issue 5398, 1999, Pages 67-70

  Barton, Gregory M ^a,b   Rudensky, Alexander Y ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ARTICLE; CELL SELECTION; CONTROLLED STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HISTOCOMPATIBILITY ANTIGENS CLASS II; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SPLEEN; THYMUS GLAND;

ANIMALIA;

EID: 0032943540     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.283.5398.67     Document Type: Article

References (42)

1. M. J. Sevan, Immunity 7, 175 (1997); P. J. Fink and M. J. Bevan, Adv. Immunol. 59, 99 (1995); G. Anderson, N. C. Moore, J. J. Owen, E. J. Jenkinson, Annu. Rev. Immunol. 14, 73 (1996); B. J. Fowlkes and E. Schweighoffer, Curr. Opin. Immunol. 7, 188 (1995); C. J. Guidos, ibid. 8, 225 (1996); C. Benoist and D. Mathis, ibid. 9, 245 (1997); P. Marrack and J. Kappler, ibid., p. 250.
2. M. J. Sevan, Immunity 7, 175 (1997); P. J. Fink and M. J. Bevan, Adv. Immunol. 59, 99 (1995); G. Anderson, N. C. Moore, J. J. Owen, E. J. Jenkinson, Annu. Rev. Immunol. 14, 73 (1996); B. J. Fowlkes and E. Schweighoffer, Curr. Opin. Immunol. 7, 188 (1995); C. J. Guidos, ibid. 8, 225 (1996); C. Benoist and D. Mathis, ibid. 9, 245 (1997); P. Marrack and J. Kappler, ibid., p. 250.
3. M. J. Sevan, Immunity 7, 175 (1997); P. J. Fink and M. J. Bevan, Adv. Immunol. 59, 99 (1995); G. Anderson, N. C. Moore, J. J. Owen, E. J. Jenkinson, Annu. Rev. Immunol. 14, 73 (1996); B. J. Fowlkes and E. Schweighoffer, Curr. Opin. Immunol. 7, 188 (1995); C. J. Guidos, ibid. 8, 225 (1996); C. Benoist and D. Mathis, ibid. 9, 245 (1997); P. Marrack and J. Kappler, ibid., p. 250.
4. M. J. Sevan, Immunity 7, 175 (1997); P. J. Fink and M. J. Bevan, Adv. Immunol. 59, 99 (1995); G. Anderson, N. C. Moore, J. J. Owen, E. J. Jenkinson, Annu. Rev. Immunol. 14, 73 (1996); B. J. Fowlkes and E. Schweighoffer, Curr. Opin. Immunol. 7, 188 (1995); C. J. Guidos, ibid. 8, 225 (1996); C. Benoist and D. Mathis, ibid. 9, 245 (1997); P. Marrack and J. Kappler, ibid., p. 250.
5. M. J. Sevan, Immunity 7, 175 (1997); P. J. Fink and M. J. Bevan, Adv. Immunol. 59, 99 (1995); G. Anderson, N. C. Moore, J. J. Owen, E. J. Jenkinson, Annu. Rev. Immunol. 14, 73 (1996); B. J. Fowlkes and E. Schweighoffer, Curr. Opin. Immunol. 7, 188 (1995); C. J. Guidos, ibid. 8, 225 (1996); C. Benoist and D. Mathis, ibid. 9, 245 (1997); P. Marrack and J. Kappler, ibid., p. 250.
6. M. J. Sevan, Immunity 7, 175 (1997); P. J. Fink and M. J. Bevan, Adv. Immunol. 59, 99 (1995); G. Anderson, N. C. Moore, J. J. Owen, E. J. Jenkinson, Annu. Rev. Immunol. 14, 73 (1996); B. J. Fowlkes and E. Schweighoffer, Curr. Opin. Immunol. 7, 188 (1995); C. J. Guidos, ibid. 8, 225 (1996); C. Benoist and D. Mathis, ibid. 9, 245 (1997); P. Marrack and J. Kappler, ibid., p. 250.
7. M. J. Sevan, Immunity 7, 175 (1997); P. J. Fink and M. J. Bevan, Adv. Immunol. 59, 99 (1995); G. Anderson, N. C. Moore, J. J. Owen, E. J. Jenkinson, Annu. Rev. Immunol. 14, 73 (1996); B. J. Fowlkes and E. Schweighoffer, Curr. Opin. Immunol. 7, 188 (1995); C. J. Guidos, ibid. 8, 225 (1996); C. Benoist and D. Mathis, ibid. 9, 245 (1997); P. Marrack and J. Kappler, ibid., p. 250.
8. K. A. Hogquist, M. A. Gavin, M. J. Bevan, J. Exp. Med. 177, 1469 (1993); P. G. Ashton-Rickardt, L. Van-Kaer, T. N. Schumacher, H. L. Ploegh, S. Tonegawa, Cell 73, 1041 (1993); K. A. Hogquist et al., ibid. 76, 17 (1994); P. G. Ashton-Rickardt et al., ibid., p. 651; E. Sebzda et al., Science 263, 1615 (1994); K. A. Hogquist et al., Immunity 6, 389 (1997); Q. Hu et al., ibid. 7, 221 (1997).
9. K. A. Hogquist, M. A. Gavin, M. J. Bevan, J. Exp. Med. 177, 1469 (1993); P. G. Ashton-Rickardt, L. Van-Kaer, T. N. Schumacher, H. L. Ploegh, S. Tonegawa, Cell 73, 1041 (1993); K. A. Hogquist et al., ibid. 76, 17 (1994); P. G. Ashton-Rickardt et al., ibid., p. 651; E. Sebzda et al., Science 263, 1615 (1994); K. A. Hogquist et al., Immunity 6, 389 (1997); Q. Hu et al., ibid. 7, 221 (1997).
10. K. A. Hogquist, M. A. Gavin, M. J. Bevan, J. Exp. Med. 177, 1469 (1993); P. G. Ashton-Rickardt, L. Van-Kaer, T. N. Schumacher, H. L. Ploegh, S. Tonegawa, Cell 73, 1041 (1993); K. A. Hogquist et al., ibid. 76, 17 (1994); P. G. Ashton-Rickardt et al., ibid., p. 651; E. Sebzda et al., Science 263, 1615 (1994); K. A. Hogquist et al., Immunity 6, 389 (1997); Q. Hu et al., ibid. 7, 221 (1997).
11. K. A. Hogquist, M. A. Gavin, M. J. Bevan, J. Exp. Med. 177, 1469 (1993); P. G. Ashton-Rickardt, L. Van-Kaer, T. N. Schumacher, H. L. Ploegh, S. Tonegawa, Cell 73, 1041 (1993); K. A. Hogquist et al., ibid. 76, 17 (1994); P. G. Ashton-Rickardt et al., ibid., p. 651; E. Sebzda et al., Science 263, 1615 (1994); K. A. Hogquist et al., Immunity 6, 389 (1997); Q. Hu et al., ibid. 7, 221 (1997).
12. K. A. Hogquist, M. A. Gavin, M. J. Bevan, J. Exp. Med. 177, 1469 (1993); P. G. Ashton-Rickardt, L. Van-Kaer, T. N. Schumacher, H. L. Ploegh, S. Tonegawa, Cell 73, 1041 (1993); K. A. Hogquist et al., ibid. 76, 17 (1994); P. G. Ashton-Rickardt et al., ibid., p. 651; E. Sebzda et al., Science 263, 1615 (1994); K. A. Hogquist et al., Immunity 6, 389 (1997); Q. Hu et al., ibid. 7, 221 (1997).
13. K. A. Hogquist, M. A. Gavin, M. J. Bevan, J. Exp. Med. 177, 1469 (1993); P. G. Ashton-Rickardt, L. Van-Kaer, T. N. Schumacher, H. L. Ploegh, S. Tonegawa, Cell 73, 1041 (1993); K. A. Hogquist et al., ibid. 76, 17 (1994); P. G. Ashton-Rickardt et al., ibid., p. 651; E. Sebzda et al., Science 263, 1615 (1994); K. A. Hogquist et al., Immunity 6, 389 (1997); Q. Hu et al., ibid. 7, 221 (1997).
14. K. A. Hogquist, M. A. Gavin, M. J. Bevan, J. Exp. Med. 177, 1469 (1993); P. G. Ashton-Rickardt, L. Van-Kaer, T. N. Schumacher, H. L. Ploegh, S. Tonegawa, Cell 73, 1041 (1993); K. A. Hogquist et al., ibid. 76, 17 (1994); P. G. Ashton-Rickardt et al., ibid., p. 651; E. Sebzda et al., Science 263, 1615 (1994); K. A. Hogquist et al., Immunity 6, 389 (1997); Q. Hu et al., ibid. 7, 221 (1997).
15. L. Ignatowicz et al., Immunity 7., 179 (1997); C. D. Surh, D. S. Lee, W. P. Fung-Leung, L. Karlsson, J. Sprent, ibid., p. 209.
16. L. Ignatowicz et al., Immunity 7., 179 (1997); C. D. Surh, D. S. Lee, W. P. Fung-Leung, L. Karlsson, J. Sprent, ibid., p. 209.
17. S. Tourne et al., ibid., p. 187;
18. W. P. Fung-Leung et al., Science 271, 1278 (1996); W. D. Martin et al., Cell 84, 543 (1996); T. Miyazaki et al., ibid., p. 531.
19. W. P. Fung-Leung et al., Science 271, 1278 (1996); W. D. Martin et al., Cell 84, 543 (1996); T. Miyazaki et al., ibid., p. 531.
20. W. P. Fung-Leung et al., Science 271, 1278 (1996); W. D. Martin et al., Cell 84, 543 (1996); T. Miyazaki et al., ibid., p. 531.
21. L. Ignatowicz, J. Kappler, P. Marrack, Cell 84, 521 (1996);
22. C. E. Grubin, S. Kovats, P. deRoos, A. Y. Rudensky, Immunity 7, 197 (1997).
23. G. M. Barton and A. Y. Rudensky, Int. Immunol. 10, 1159 (1998).
24. 1 X IiKO embryos. Integration into the mouse germ line was assessed by polymerase chain reaction amplification of tail DNA from the progeny of transgenic founders, with primers specific for the Ii-pEα transgene.
25. G. M. Barton and A. Y. Rudensky, data not shown.
26. L. Denzin, personal communication.
27. S. Tourne et al., Proc Natl. Acad. Sci. U.S.A. 94, 9255 (1997).
28. S. Kovats et al., J. Exp. Med. 187, 245 (1998).
29. G. M. Barton and A. Y. Rudensky, data not shown.
30. KO lymph node cells developed significant proliferative responses to C57B/6 stimulators.
31. KO chimeras were deleted.
32. D. B. Murphy et al., Nature 338, 765 (1989).
33. A. Y. Rudensky, S. Rath, P. Preston-Hurlburt, D. B. Murphy, C. A. Janeway Jr., ibid. 353, 660 (1991); A. Y. Rudensky, unpublished observations.
34. H. Pircher, U. H. Rohrer, D. Moskophidis, R. M. Zinkernagel, H. Hengartner, Nature 351, 482 (1991); J. Yagi and C. A. Janeway Jr., Int. Immunol. 2, 83 (1990); K. A. Hogquist, S. C. Jameson, M. J. Bevan, Immunity 3, 79 (1995).
35. H. Pircher, U. H. Rohrer, D. Moskophidis, R. M. Zinkernagel, H. Hengartner, Nature 351, 482 (1991); J. Yagi and C. A. Janeway Jr., Int. Immunol. 2, 83 (1990); K. A. Hogquist, S. C. Jameson, M. J. Bevan, Immunity 3, 79 (1995).
36. H. Pircher, U. H. Rohrer, D. Moskophidis, R. M. Zinkernagel, H. Hengartner, Nature 351, 482 (1991); J. Yagi and C. A. Janeway Jr., Int. Immunol. 2, 83 (1990); K. A. Hogquist, S. C. Jameson, M. J. Bevan, Immunity 3, 79 (1995).
37. J. Kaye et al., Nature 341, 746 (1989).
38. P. Wong and A. Y. Rudensky, in preparation.
39. M. Liljedahl et al., Immunity 8, 233 (1998).
40. b (22)], followed by streptavidin-fluorescein isothiocyanate (FITC) (Vector). Stained cells were analyzed by a FACScan flow cytometer (Becton-Dickinson).
41. Thymocytes or erythrocyte-depleted splenocytes were incubated on ice with anti-CD4-phycoerythrin, anti-CD8α- FITC, and anti-TCRβ-biotin mAbs (all from Pharmingen) followed by streptavidin-Tricolor (Caltag). Stained cells were analyzed by a FACScan flow cytometer (Becton-Dickinson).
42. We thank A. W. Goldrath for helpful discussions and advice, M. J. Bevan and P. J. Fink for comments on the manuscript, S. Eastman for technical assistance, C. Wilson for generation of transgenic mice, and D. Wilson for maintenance of mice. Care of all experimental animals was in accordance with the guidelines of the University of Washington. Supported by a Hall-Ammerer Memorial Fellowship (G.M.B.), the NIH (A.Y.R.), and the Howard Hughes Medical Institute (A.Y.R.).